Fierce Biotech Homepage

saker falcon
Favicon Fierce Biotech

Ipsen fails to land pivotal rare disease trial

Ipsen’s miss follows Regeneron's phase 3 win in the same ultrarare indication. Regeneron said it planned for a FDA submission by the end of 2025.
Gabrielle Masson Dec 19, 2025 3:37pm
next step ladder climb succeed win
Favicon Fierce Biotech

Altimmune eyes phase 3 MASH trial as weight loss deepens

Dec 19, 2025 8:30am
Alps parachute rainbow mountains
Favicon Fierce Biotech

Pfizer RNA leader runs to Replicate—Chutes & Ladders

Dec 19, 2025 8:30am
Orange star symbol glowing amid black star symbols on black background
Favicon Fierce Biotech

Fierce Biotech's 2025 must-reads

Dec 19, 2025 7:00am
Medline truck
Favicon Fierce Biotech

Medline makes Nasdaq debut, raising $6.26B in year's largest IPO

Dec 17, 2025 11:11am
FDA
Favicon Fierce Pharma

12 former FDA chiefs blast Prasad's vaccine policy shake-ups

Dec 4, 2025 10:36am
More News
Fierce Biotech

FDA adopts agentic artificial intelligence in latest AI push

Dec 1, 2025 5:33pm
Fierce Biotech

GE HealthCare to acquire Intelerad for $2.3B

Nov 20, 2025 4:34pm

CDC updates website to promote debunked vaccine-autism link

Nov 20, 2025 4:20pm
Fierce Biotech

Abbott inks $23B deal for Exact Sciences in cancer testing buy

Nov 20, 2025 10:30am